Szederjesi Janos, Săplăcan Irina, Petrișor Marius, Șerdean Alexandra-Maria, Grigorescu Bianca-Liana
Department of Intensive Care, George Emil Palade University of Medicine, Pharmacy, Science and Technology, 540139 Târgu-Mureș, Romania.
Department of Simulation Applied in Medicine, University of Medicine, Pharmacology, Science and Technology, 540139 Târgu-Mureș, Romania.
Life (Basel). 2024 Sep 26;14(10):1232. doi: 10.3390/life14101232.
(1) Background: Since the onset of the COVID-19 pandemic, it has been recognized that a considerable proportion of critically ill patients may die of this disease. The current study aims to assess the overall 1-year outcomes within the UMFST COVID-19 Unit, providing valuable insights into the efficacy of specialized care facilities in managing severe cases of COVID-19. (2) Methods: This is a retrospective monocentric observational study including 294 patients confirmed to have SARS-CoV-2 infection. Demographic data and clinical and paraclinical parameters were assessed. Survival probabilities were estimated using Kaplan-Meier curves. (3) Results: Overall, the 1-year mortality was 89.4%. All deaths occurred in-hospital, with two patients dying after 28 days. Diabetes mellitus, chronic kidney failure, cerebrovascular disease, and atrial fibrillation were more prevalent in deceased patients. Thirty percent of patients needed endotracheal intubation during the first 24 h. The incidence of hospital-acquired pneumonia was higher among deceased patients. The SOFA score was significantly different between deceased vs. survivors. The survival analysis showed that the use of noradrenaline increased the likelihood of surviving COVID-19. (4) Conclusions: The severe comorbidities of the patients were the primary factors contributing to the increased mortality rate in the COVID-19 unit.
(1) 背景：自新冠疫情爆发以来，人们已经认识到相当一部分危重症患者可能死于该疾病。本研究旨在评估乌姆弗斯特新冠治疗单元内患者的总体1年预后情况，为专门护理设施在管理新冠重症病例方面的疗效提供有价值的见解。(2) 方法：这是一项回顾性单中心观察性研究，纳入了294例确诊感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的患者。评估了人口统计学数据以及临床和辅助临床参数。使用Kaplan-Meier曲线估计生存概率。(3) 结果：总体而言，1年死亡率为89.4%。所有死亡均发生在医院内，有2例患者在28天后死亡。糖尿病、慢性肾衰竭、脑血管疾病和心房颤动在死亡患者中更为常见。30%的患者在最初24小时内需要气管插管。死亡患者中医院获得性肺炎的发生率更高。序贯器官衰竭评估（SOFA）评分在死亡患者和存活患者之间存在显著差异。生存分析表明，使用去甲肾上腺素可增加新冠患者存活的可能性。(4) 结论：患者的严重合并症是导致新冠治疗单元死亡率升高的主要因素。
